Cargando…

Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy

BACKGROUND: Treatment of moderate to severe Graves’ orbitopathy (GO) is based mainly on intravenous pulses of methylprednisolone. High doses of methylprednisolone can exert several adverse effects, some of which might be life-threatening. The objective of this study is to describe the most severe co...

Descripción completa

Detalles Bibliográficos
Autores principales: Walasik-Szemplińska, Dorota, Kamiński, Grzegorz, Sudoł-Szopińska, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927113/
https://www.ncbi.nlm.nih.gov/pubmed/31890036
http://dx.doi.org/10.1186/s13044-019-0074-0
_version_ 1783482242379546624
author Walasik-Szemplińska, Dorota
Kamiński, Grzegorz
Sudoł-Szopińska, Iwona
author_facet Walasik-Szemplińska, Dorota
Kamiński, Grzegorz
Sudoł-Szopińska, Iwona
author_sort Walasik-Szemplińska, Dorota
collection PubMed
description BACKGROUND: Treatment of moderate to severe Graves’ orbitopathy (GO) is based mainly on intravenous pulses of methylprednisolone. High doses of methylprednisolone can exert several adverse effects, some of which might be life-threatening. The objective of this study is to describe the most severe complications associated with intravenous administration of high doses of glucocorticoids, and to develop the patient examination standards prior to their qualification for the therapy. MAIN BODY: In this paper, we describe the most severe, life-threatening complications of intravenous methylprednisolone and address their possible underlying mechanism. We also present recommendations and precautions which should be taken prior to initiation of intravenous pulses of methylprednisolone treatment for GO. To address risk of hepatic complications, we recommend regular monitoring of biochemical parameters of hepatic function. Additionally, assessment of the risk of cardiovascular events should be undertaken based on medical history, estimation of risk factors, and investigations, such as determination of thyroid hormones and thyroid-stimulating hormone levels, electrolyte and glucose concentrations, electrocardiogram examination and measurements of blood pressure. CONCLUSIONS: An individualized safe and effective dose of intravenous methylprednisolone should be established for each patient with GO based on the vascular risk factors, comorbidities, and concomitant drugs. According to the European Group on Graves’ Orbitopathy (EUGOGO) guidelines, cumulative doses of intravenous methylprednisolone should not exceed 8 g.
format Online
Article
Text
id pubmed-6927113
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69271132019-12-30 Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy Walasik-Szemplińska, Dorota Kamiński, Grzegorz Sudoł-Szopińska, Iwona Thyroid Res Review BACKGROUND: Treatment of moderate to severe Graves’ orbitopathy (GO) is based mainly on intravenous pulses of methylprednisolone. High doses of methylprednisolone can exert several adverse effects, some of which might be life-threatening. The objective of this study is to describe the most severe complications associated with intravenous administration of high doses of glucocorticoids, and to develop the patient examination standards prior to their qualification for the therapy. MAIN BODY: In this paper, we describe the most severe, life-threatening complications of intravenous methylprednisolone and address their possible underlying mechanism. We also present recommendations and precautions which should be taken prior to initiation of intravenous pulses of methylprednisolone treatment for GO. To address risk of hepatic complications, we recommend regular monitoring of biochemical parameters of hepatic function. Additionally, assessment of the risk of cardiovascular events should be undertaken based on medical history, estimation of risk factors, and investigations, such as determination of thyroid hormones and thyroid-stimulating hormone levels, electrolyte and glucose concentrations, electrocardiogram examination and measurements of blood pressure. CONCLUSIONS: An individualized safe and effective dose of intravenous methylprednisolone should be established for each patient with GO based on the vascular risk factors, comorbidities, and concomitant drugs. According to the European Group on Graves’ Orbitopathy (EUGOGO) guidelines, cumulative doses of intravenous methylprednisolone should not exceed 8 g. BioMed Central 2019-12-23 /pmc/articles/PMC6927113/ /pubmed/31890036 http://dx.doi.org/10.1186/s13044-019-0074-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Walasik-Szemplińska, Dorota
Kamiński, Grzegorz
Sudoł-Szopińska, Iwona
Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy
title Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy
title_full Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy
title_fullStr Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy
title_full_unstemmed Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy
title_short Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy
title_sort life-threatening complications of high doses of intravenous methylprednisolone for treatment of graves’ orbitopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927113/
https://www.ncbi.nlm.nih.gov/pubmed/31890036
http://dx.doi.org/10.1186/s13044-019-0074-0
work_keys_str_mv AT walasikszemplinskadorota lifethreateningcomplicationsofhighdosesofintravenousmethylprednisolonefortreatmentofgravesorbitopathy
AT kaminskigrzegorz lifethreateningcomplicationsofhighdosesofintravenousmethylprednisolonefortreatmentofgravesorbitopathy
AT sudołszopinskaiwona lifethreateningcomplicationsofhighdosesofintravenousmethylprednisolonefortreatmentofgravesorbitopathy